Toggle light / dark theme

This Company is Making Bodiless Heads 😳 | Mattcast #567

Is this the most controversial biotech advancement yet? 🧠 Inside this sneak peek of Mattcast #567, we break down a groundbreaking medical tech company testing on bodiless heads for neurological research.

New standard video episodes drop weekly! Hit follow to never miss a breakdown of the wildest advancements in future science and tech news.

#Biotech #MedicalTech #FutureScience #Mattcast #Neurology #TechNews #Walljangers #TechPodcast #Neuroscience #BiotechNews #SciFiTech

The Science of Human Potential: How the Brain Shapes Aging, Health & Performance | Dr. Srini Pillay

What if aging isn’t just biology
but also psychology — and your brain is quietly shaping how fast you age every day?

Dr. Srini Pillay, MD (https://drsrinipillay.com/) is a Harvard-trained psychiatrist, brain researcher, entrepreneur, author, and expert in the science of human potential, resilience, and longevity.

Dr. Pillay previously served as Assistant Professor of Psychiatry at Harvard Medical School and directed both the Outpatient Anxiety Disorders Program and the Panic Disorders Research Program in Brain Imaging at McLean Hospital, one of the world’s leading psychiatric institutions.

Over the course of his career, Dr. Pillay has focused on understanding how the brain shapes performance, creativity, emotional health, leadership, and even biological aging. His work bridges neuroscience, psychiatry, technology, and human behavior — translating cutting-edge brain science into practical tools for individuals, organizations, and healthcare systems.

Dr. Pillay is the co-founder and Chief Medical Officer of Reulay (https://www.reulay.com/), an AI-driven digital therapeutics and mindset technology company focused on healthy longevity, stress reduction, and human performance. He is also founder of the NeuroBusiness Group (https://nbgcorporate.com/), where he works with leaders and organizations around the world on brain-based approaches to innovation, adaptability, resilience, and navigating complexity in the age of AI.

Dr. Pillay is the author of several influential books including Tinker Dabble Doodle Try (https://www.amazon.com/Tinker-Dabble-?tag=lifeboatfound-20
 which explores the neuroscience of creativity and the untapped power of the brain’s unconscious processing systems.

Vulnerable ALS neurons reveal molecular warning signs before cell death begins

A new study from the Knight Initiative for Brain Resilience researchers may help explain an enduring mystery about amyotrophic lateral sclerosis (ALS): why the disease kills off some of the brain and spinal cord’s movement-controlling neurons while others show greater resilience.

As ALS progresses, more and more of those motor neurons degenerate and die. As a result, patients lose control of their bodies and become unable to breathe. Many people are diagnosed in middle to late adulthood, and most survive only three to five years after diagnosis.

“It’s a cruelly rapid disease,” said Olivia Gautier, a postdoctoral scholar in the lab of Knight Initiative researcher Aaron Gitler, the Stanford Medicine Basic Science Professor and a professor of genetics at Stanford Medicine.

The Placenta: The Organ That Programs Human Health Before Birth | Dr. Perrie O’Tierney-Ginn

Dr. Perrie O’Tierney-Ginn, Ph.D. — Executive Director of the Woman, Mother & Baby Research Institute — Tufts.


Before your heart, brain, or lungs fully developed, one remarkable temporary organ was making decisions that may influence your health for decades. Dr. Perrie O’Tierney-Ginn (https://www.placentascience.com/) explains why the placenta could be the most important organ you’ve never thought about.

Dr. Perrie O’Tierney-Ginn, Ph.D. is Executive Director of the Woman, Mother & Baby Research Institute at Tufts Medical Center (https://www.tuftsmedicine.org/researc
 and a Research Associate Professor in both Obstetrics & Gynecology at Tufts University School of Medicine (https://www.tuftsmedicine.org/researc
 and the Friedman School of Nutrition Science and Policy (https://nutrition.tufts.edu/academics
).

A self-described \.

Iron accumulation in the brain may contribute to neurodegeneration

Neurodegenerative diseases affect tens of millions of people worldwide. Among these, Alzheimer’s and Parkinson’s diseases are the most common; in the United States alone, the Alzheimer’s Disease Association and Parkinson’s Foundation report roughly 7 million people with Alzheimer’s and another million with Parkinson’s. An intriguing clue lies in the tangled mystery of neurodegeneration that scientists are working to solve: iron accumulation.

Scientists have noticed that iron can slowly build up inside neurons. Early in life, this iron accumulation appears to have little effect on neuronal function. However, later in life, it can contribute to a slow neuronal demise. Salk Institute researchers studied nerve cells to figure out whether and how this iron accumulation relates to neurodegenerative diseases. They found that the excess iron stuck in neurons lowers the cells’ defenses, making them more vulnerable to stressors and other cellular insults through a process they named chronoferroptosis.

The study, published in Cell Death Discovery on June 18, 2026, points to iron accumulation as a key target in the effort to predict, prevent and treat neurodegenerative diseases.

Sleep deprivation increases levels of the synaptic density marker SV2A in the human brain

The synaptic homeostasis hypothesis posits that sleep is essential for restoring cerebral equilibrium by downscaling synaptic connections that progressively strengthen and accumulate metabolic costs during wakefulness. While previously supported only by preclinical animal models, a recent study provides direct in vivo evidence of this mechanism in humans. Researchers evaluated 40 volunteers, half of whom underwent 28 hours of continuous sleep deprivation, utilizing Positron Emission Tomography (PET) to quantify levels of the SV2A protein, a reliable biomarker for synaptic density. The findings revealed that prolonged wakefulness significantly elevated SV2A levels across multiple brain regions, most notably in the hippocampus and thalamus. Furthermore, during a subsequent two-hour recovery sleep period, these elevated SV2A levels were strongly correlated with enhanced slow-wave activity, a primary electrophysiological marker of deep sleep and homeostatic sleep pressure. These results validate the synaptic homeostasis hypothesis in humans, demonstrating a measurable biological link between sleep deprivation, the accumulation of neural connections, and the restorative drive for deep, slow-wave sleep.


The synaptic homeostasis hypothesis (SHY) [1– 4] posits that wakefulness promotes synaptic potentiation due to environmental interactions and learning [5]. The strengthening of connections during waking elevates energy consumption, results in the accumulation of proteins and receptors that compete for the limited anatomical space in the skull and diminishes the signal-to-noise ratios in the neuronal network, ultimately saturating the capacity for learning. Sleep allows for synaptic down-selection, preserving energy and network efficiency. While the SHY has been supported by anatomical and molecular studies in animals, human evidence has remained limited due to the invasive nature of most techniques for quantifying synaptic strength.

Studies in animals indicate that anatomical or molecular markers of synaptic strength increase during wake and decline during sleep [6]. Firing rates in rodents indicate increased cortical excitability during wakefulness and decreased cortical excitability during sleep. In humans, cortical excitability is an indirect measure of plasticity. Findings from studies using transcranial magnetic stimulation (TMS) translated the findings from the above-mentioned rodent studies (reviewed in [7]). However, some in-vitro and in-vivo studies of synaptic strength in animals reveal opposite results, which may be due to differences in the type of marker, examined brain regions, cortical layers, or housing of animals (reviewed in [8]).

Synaptic vesicle glycoprotein 2A (SV2A) [9] is an integral membrane protein located on synaptic vesicles. Recent advances in PET imaging with tracers such as [Âč⁞F]SynVesT-1 enable the noninvasive measurement of SV2A binding in the living human brain [10,11], allowing new opportunities to examine state-dependent synaptic changes. However, whether this reflects presynaptic terminal number, vesicle complement, SV2A expression per vesicle, or excitatory/inhibitory-synapse composition cannot be resolved with in vivo imaging. While SV2A availability is commonly interpreted as a proxy measure of synaptic density, we refer to it here as ‘SV2A-indexed synaptic density’ to reflect this interpretation while acknowledging its underlying biological ambiguity.

Sugar-coated nanoparticles show promise for treating most aggressive form of brain cancer

Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.

The study, led by Oleh Taratula, Olena Taratula and Yoon Tae Goo of the OSU College of Pharmacy, addresses what they describe as the two most persistent obstacles to effective glioblastoma treatment: delivering therapeutic agents through the blood-brain barrier, the cell network that acts as a security checkpoint between the bloodstream and the central nervous system, and then getting those agents to preferentially target tumors.

In research published in the Journal of Controlled Release, the scientists demonstrate the novel treatment technique in a mouse model. They loaded lipid nanoparticles with genetic material that promotes tumor suppression, then coated the nanoparticles with a type of sugar. The result was a 50% median increase in glioblastoma survival time.

Can Mind-Reading Tech Help People Hear Better?

From Vishal Choudhari, PhD, and the lab of Nima Mesgarani, PhD, at Columbia University’s Zuckerman Institute: A new tech monitors the brain to detect who you are listening to. It then amplifies that voice and quiets other voices nearby. Brain surgery patients recently tested the system in hospitals. They heard two overlapping conversations, one on each side. The volunteers then tried to focus on only one conversation. One video here shows a man listening to the overlapping conversations. Researchers ask him to focus on the conversation on his right. Controlled by his brain activity, the system adjusts the volume. In another experiment, he again focuses his attention on the right. The system notices, amplifying a conversation about bread. Then, researchers ask him to switch to the left conversation. The mind reading system turns about another conversation, about repairs. In a different experience, a volunteer can freely choose what to listen to. He starts on the right. A graph appears, showing the system monitoring his brain activity. What happens when he switches from right to left? The system spots his shift in attention and adjusts the volume. Scientists asked volunteers about the experience. “In the second section, what I was listening to was louder, and the other thing was quieter. And in the first section, they were both equally loud. That’s super dope.” “I think if you could really implement it in the hearing aids, if this is the goal, I think it would be really helpful to just be able to have someone who is hard of hearing be able to kind of pinpoint exactly the conversation they want to have, especially if you’re in a location with a lot of people.” “Well I just keep thinking about about Uncle Aaron. Can you imagine if this technology existed in a world that he could access it? He might actually live a much more peaceful
 life.”

/* */